37.40USD-4.75%Mkt Cap: 1.78B USDP/E: —Last update: 2026-06-01
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous sy…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap1.78B USD
Enterprise Value1.42B USD
Revenue (TTM)20.00M USD
Gross Profit6.86M USD
Net Income (TTM)-111.48M USD
Revenue/Share0.4770 USD
Last Price37.40 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees84
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-8.84
PEG—
EV/EBITDA-11.74
EV/Revenue71.16
P/S94.46
P/B4.00
EPS (TTM)-2.60
EPS (Forward)-4.47
52W Range
7.73086% of range42.27
52W High42.27 USD
52W Low7.730 USD
Profitability
Gross Margin34.28%
Oper. Margin-121.08%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-23.00%
ROA-21.76%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-87.47M USD
CapEx (TTM)616.00K USD
FCF Margin-247.16%
FCF Yield-2.78%
Net Debt-465.98M USD
Net Debt/EBITDA3.84
Balance Sheet
Debt/Equity0.02
Current Ratio27.08
Quick Ratio26.64
Book Value/Sh9.863 USD
Cash/Share9.969 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.1 (Strong Buy)
Target (Mean)57.10 USD
Target Range40.00 USD – 80.00 USD
# Analysts10
Ownership
Shares Out.47.83M
Float31.75M
Insiders4.65%
Institutions109.22%
Short Interest
Short Ratio6.3d
Short % Float8.01%
Short % Out.5.05%
Shares Short2.42M
Short (prev mo.)3.41M
Technical
SMA 5034.82 (+7.4%)
SMA 20028.40 (+31.7%)
Beta—
S&P 52W Chg27.70%
Avg Vol (30d)288.35K
Avg Vol (10d)281.03K
Technical Indicators
RSI (14)60.4
MACD1.0637
MACD Signal0.9246
MACD Hist.+0.1391
BB Upper40.86 USD
BB Middle37.29 USD
BB Lower33.72 USD
BB Width19.13%
ATR (14)2.053 USD
Vol Ratio (20d)0.42x